GLOBUS MEDICAL, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$826M
↑+25.7% +$169Mvs FY2024 (Q4)
Gross Profit
$565M
↑+43.5% +$171Mvs FY2024 (Q4)
Operating Income
$169M
↑+181.0% +$109Mvs FY2024 (Q4)
Net Income
$141M
↑+470.0% +$116Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $826M | $657M |
| COGS | $261M | $263M |
| Gross Profit | $565M | $394M |
| R&D | $36M | $33M |
| SG&A | $318M | $253M |
| D&A | $41M | $47M |
| Other OpEx | $0 | $0 |
| Operating Income | $169M | $60M |
| Interest Exp. | $107K | $36M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $169M | $25M |
| Tax | $29M | $0 |
| Net Income | $141M | $25M |
QuarterCharts · SEC EDGAR data · GMED · Comparing FY2025 (Q4) vs FY2024 (Q4)